Emerald BioStructures, the contract research firm in Bainbridge Island, WA, said today it has formed a new collaboration with Boulder, CO-based SomaLogic. The deal calls for Emerald to provide its expertise in determining precise crystal structures of protein targets on cells, so that SomaLogic can make specific “aptamer” drugs, and small molecules, that bind tightly with the chosen target. Financial terms weren’t disclosed. But this is the second notable deal this year for Emerald, following a partnership with Cambridge, MA-based Forma Therapeutics. For more on the intriguing backstory of Emerald, check out this feature story I wrote back in May.